Articles dans des revues avec comité de lecture (50)
  1. 23. Vertongen, P., Solano Haro, R., Juarranz Moratilla, M. G., Perret, J., Waelbroeck, M., & Robberecht, P. (2001). Proline residue 280 in the second extracellular loop (EC2) of the VPAC2 receptor is essential for the receptor structure. Peptides, 22(9), 1363-1370. doi:10.1016/S0196-9781(01)00476-4
  2. 24. Vertongen, P., Solano Haro, R., Perret, J., Langer, I., Robberecht, P., & Waelbroeck, M. (2001). Mutational analysis of the human vasoactive intestinal peptide receptor subtype VPAC(2): role of basic residues in the second transmembrane helix. British Journal of Pharmacology, 133(8), 1249-1254. doi:10.1038/sj.bjp.0704195
  3. 25. Solano Haro, R., Langer, I., Perret, J., Vertongen, P., Juarranz Moratilla, M. G., Robberecht, P., & Waelbroeck, M. (2001). Two basic residues of the h-VPAC1 receptor second transmembrane helix are essential for ligand binding and signal transduction. The Journal of biological chemistry, 276(2), 1084-1088. doi:10.1074/jbc.M007696200
  4. 26. Langer, I., Vertongen, P., Perret, J., Fontaine, J., Atassi, G., & Robberecht, P. (2000). Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in human neuroblastomas. Medical and pediatric oncology, 34(6), 386-393.
  5. 27. Dewit, D., Gourlet, P., Amraoui, Z., Vertongen, P., Willems, F., Robberecht, P., & Goldman, M. (1998). The vasoactive intestinal peptide analogue RO25-1553 inhibits the production of TNF and IL-12 by LPS-activated monocytes. Immunology letters, 60(1), 57-60. doi:10.1016/S0165-2478(97)00129-6
  6. 28. Vertongen, P., Schiffmann, S. N., Gourlet, P., & Robberecht, P. (1998). Autoradiographic visualization of the receptor subclasses for vasoactive intestinal polypeptide (VIP) in rat brain. Annals of the New York Academy of Sciences, 865, 412-415. doi:10.1111/j.1749-6632.1998.tb11206.x
  7. 29. Vertongen, P., De Clerck, P., Fournet, J.-C., Martelli, H., Hélardot, P., Devalck, C., Peeters, T., Sariban, E., & Robberecht, P. (1997). Comparison between vasoactive intestinal polypeptide and pituitary adenylate cyclase activating polypeptide levels in neuroblastoma tumour tissues. Neuropeptides, 31(5), 409-413.
  8. 30. Jordaens, L., Trouerbach, J., Calle, P., Tavernier, R., Derycke, E., Vertongen, P., Bergez, B., & Vandekerckhove, Y. (1997). Conversion of atrial fibrillation to sinus rhythm and rate control by digoxin in comparison to placebo. European heart journal, 18(4), 643-648.
  9. 31. Vertongen, P., Schiffmann, S. N., Gourlet, P., & Robberecht, P. (1997). Autoradiographic visualization of the receptor subclasses for vasoactive intestinal polypeptide (VIP) in rat brain. Peptides, 18(10), 1547-1554. doi:10.1016/S0196-9781(97)00229-5
  10. 32. Gourlet, P., Vertongen, P., Vandermeers, A., Vandermeers-Piret, M.-C., Rathe, J., De Neef, P., Waelbroeck, M., & Robberecht, P. (1997). The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass. Peptides, 18(3), 403-408. doi:10.1016/S0196-9781(96)00322-1
  11. 33. Gourlet, P., Vandermeers, A., Vertongen, P., Rathe, J., De Neef, P., Cnudde, J., Waelbroeck, M., & Robberecht, P. (1997). Development of high affinity selective VIP1 receptor agonists. Peptides, 18(10), 1539-1545. doi:10.1016/S0196-9781(97)00228-3
  12. 34. Vertongen, P., Camby, I., Darro, F., Kiss, R., & Robberecht, P. (1996). VIP and pituitary adenylate cyclase activating polypeptide (PACAP) have an antiproliferative effect on the T98G human glioblastoma cell line through interaction with VIP2 receptor. Neuropeptides, 30(5), 491-496.
    13. << Précédent 1 2 3 4 5 Suivant >>